IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Estimates By $0.33 EPS

IDEXX Laboratories (NASDAQ:IDXX) issued its quarterly earnings data on Tuesday. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33, Zacks reports. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the firm earned $3.50 earnings per share. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories updated its FY 2026 guidance to 14.690-14.940 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Strong second-quarter performance: Revenue grew 10% reported and 9% organically, while comparable EPS increased 15% to $4.27. IDEXX raised its full-year revenue outlook to $4.70 billion–$4.745 billion and EPS outlook to $14.69–$14.94.
• CAG Diagnostics recurring revenue grew 10.3% organically, including nearly 10% growth in the U.S. and nearly 12% internationally, driven by testing volumes, customer additions, instrument placements and higher utilization.
• Innovation momentum remained strong, with 1,602 inVue Dx placements in the quarter and 2,700 year-to-date, keeping the company on pace for its 5,500-unit annual goal. The controlled rollout of inVue Dx FNA is expanding in the third quarter, with broad availability planned by year-end, while Cancer Dx surpassed 10,000 ordering clinics.
• U.S. same-store clinical visits declined 1.3%, with wellness visits down nearly 3%, and IDEXX expects a similar approximately 1.5% decline in the second half. Management cited consumer economic pressure and slower pet adoption trends as ongoing constraints.
• Comparable operating margin expanded 110 basis points to approximately 35% in the second quarter, but IDEXX plans additional commercial, R&D, IT and AI investments in the second half. The company also expects foreign exchange to create a $15 million full-year revenue headwind, partly offsetting operational improvements.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded down $5.78 during midday trading on Wednesday, reaching $582.31. 233,275 shares of the stock traded hands, compared to its average volume of 583,517. The stock has a market cap of $45.93 billion, a P/E ratio of 42.88, a PEG ratio of 3.11 and a beta of 1.54. The stock’s fifty day moving average is $558.15 and its 200-day moving average is $587.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent research reports. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Citigroup reiterated a “neutral” rating on shares of IDEXX Laboratories in a research note on Wednesday. UBS Group lowered their target price on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research note on Monday, July 27th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $749.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IDXX. Compound Planning Inc. grew its stake in shares of IDEXX Laboratories by 51.9% in the 4th quarter. Compound Planning Inc. now owns 1,802 shares of the company’s stock worth $1,219,000 after buying an additional 616 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of IDEXX Laboratories by 13.8% in the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after acquiring an additional 181,955 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 37.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 1,707 shares of the company’s stock worth $1,155,000 after purchasing an additional 465 shares during the period. Birchwood Financial Partners Inc. purchased a new stake in IDEXX Laboratories in the 4th quarter worth about $82,000. Finally, Corient Private Wealth LLC lifted its stake in IDEXX Laboratories by 58.9% in the fourth quarter. Corient Private Wealth LLC now owns 184,587 shares of the company’s stock worth $124,879,000 after purchasing an additional 68,410 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Quarterly results exceeded expectations. IDEXX reported second-quarter EPS of $4.27, above the roughly $3.94-$3.95 analyst consensus, while revenue reached $1.217 billion versus expectations of approximately $1.20 billion. Revenue increased about 10% year over year, or 9% organically. IDEXX Laboratories Announces Second Quarter Results
• Positive Sentiment: Growth was broad-based. Companion Animal Group revenue rose 9%, Water revenue increased 15% as reported, and Livestock, Poultry and Dairy revenue grew 11%. Analysts also highlighted margin expansion and ongoing adoption of IDEXX’s diagnostic products as growth drivers. IDXX Q2 Earnings and Revenues Beat, 2026 EPS View Up
• Positive Sentiment: Fiscal 2026 guidance was raised. IDEXX provided EPS guidance of $14.69-$14.94, above the $14.64 consensus estimate. Revenue guidance was set at approximately $4.7 billion, in line with expectations, reinforcing confidence in earnings growth. IDEXX Laboratories Jumps on Strong Results and Raised Guidance
• Neutral Sentiment: Valuation remains elevated. Despite the strong report, IDEXX trades at a premium earnings multiple, which could limit further gains or increase sensitivity to any slowdown in veterinary demand or future guidance.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.